Eager to address Indonesia’s pressing healthcare and food security needs with localised biotechnology, Revata Utama leads Nusantics, which excels at advanced molecular diagnostics for early disease detection. Previously its CTO, his technical leadership was crucial in developing Indonesia’s first local COVID-19 PCR tests. In 2023, he became CEO and helped Nusantics recover from the brink of bankruptcy. Business has since stabilised, and it has introduced pioneering urine-based HPV screening for early cervical cancer detection and expanded into animal health with diagnostics for Indonesia’s shrimp industry.

Impacted Industries